MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
Trial details
- Registry ID
- NCT06128629
- Phase
- Phase 3
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)NCT06128629 | Intellia Therapeutics | Phase 3 | Recruiting | 2027-12Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |